Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:39 AM
Ignite Modification Date:
2025-12-25 @ 12:39 AM
NCT ID:
NCT06941467
Eligibility Criteria:
Inclusion Criteria:
* Be scheduled to undergo MMS at 234 East 85th St for a skin cancer that is deemed Mohs
* Appropriate by the Mohs surgery appropriate use criteria
* Have an open surgical wound \< 4 cm and \> 0.5 cm
* Be ≥18 years of age
* English-speaking
* Provide a signed and dated informed consent form
* State willingness to comply with all study procedures
Exclusion Criteria:
* Age less than 18 years of age
* Open surgical wound \> 4 cm
* If tumor clearance cannot be achieved with MMS
* Pregnant women
* Breastfeeding women
* Patients who are taking oral beta-blockers (ie oral timolol, metoprolol, carvedilol, propranolol, atenolol)
* Patients who are currently taking any of the following medications: clonidine, digoxin, methyldopa, quinidine, fluoxetine and paroxetine, bupropion
* Patient currently taking a calcium channel blocker AND has pre-existing heart failure as defined by a reduced ejection fraction
* Patients with pre-existing hypotension
* Pre-existing diagnosis of sinus bradycardia
* Pre-existing diagnosis of second or third degree atrioventricular block
* Congestive heart failure
* Pre-existing diagnosis of severe asthma
* Pre-existing diagnosis of chronic obstructive pulmonary disease
* Any known hypersensitivity to 0.5% timolol solution
* Patients who have a wound where primary closure is feasible and desired by the patient
* Defect size \<0.5 cm
* Prior sensitivity or known allergy to timolol
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06941467
Study Brief:
Protocol Section:
NCT06941467